B7IG fusion protein
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 3, 1996
Grant Date -
N/A
app pub date -
Mar 29, 1994
filing date -
Mar 26, 1990
priority date (Note) -
In Force
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | Total Patents |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | PRINCETON, NJ | 2048 |
International Classification(s)

- [Classification Symbol]
- [Patents Count]
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Brady, William | Bothell, WA | 44 | 1353 |
Damle, Nitin K | Renton, WA | 32 | 1177 |
Ledbetter, Jeffrey A | Seattle, WA | 120 | 4171 |
Linsley, Peter S | Seattle, WA | 84 | 2695 |
Cited Art Landscape
Patent Info | (Count) | # Cites | Year |
---|---|---|---|
|
|||
* 5336603 CD4 adheson variants | 174 | 1992 | |
|
|||
* 4399216 Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials | 638 | 1980 | |
|
|||
* 4683202 Process for amplifying nucleic acid sequences | 4097 | 1985 | |
* 4683195 Process for amplifying, detecting, and/or-cloning nucleic acid sequences | 3538 | 1986 |
Patent Citation Ranking
Forward Cite Landscape
Patent Info | (Count) | # Cites | Year |
---|---|---|---|
|
|||
* 2003/0219,436 Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein | 18 | 2002 | |
* 2004/0054,158 GL50 molecules and uses therefor | 5 | 2002 | |
* 2006/0115,484 Apo-2 receptor | 7 | 2005 | |
* 2006/0084,147 Apo-2 receptor | 11 | 2005 | |
* 2006/0073,570 Apo-2 receptor | 11 | 2005 | |
8435952 Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis | 4 | 2011 | |
|
|||
6682741 .beta.2 microglobulin fusion proteins and high affinity variants | 9 | 2001 | |
* 2004/0091,492 Beta2 microglobulin fusion proteins and high affinity variants | 0 | 2003 | |
|
|||
8409577 Single chain multivalent binding proteins with effector function | 7 | 2007 | |
|
|||
* 2004/0009,528 Protein chips | 2 | 2002 | |
|
|||
* 2002/0102,232 Compositions and methods for induction of active autoimmunity | 0 | 2001 | |
|
|||
* 6887471 Method to inhibit T cell interactions with soluble B7 | 21 | 1999 | |
* 2002/0031,510 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith | 34 | 2001 | |
7094874 Soluble CTLA4 mutant molecules | 30 | 2001 | |
* 2002/0182,211 Soluble CTLA4 mutant molecules and uses thereof | 22 | 2001 | |
* 2002/0039,577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes | 28 | 2001 | |
* 2003/0083,246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule | 10 | 2001 | |
7304033 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | 32 | 2002 | |
* 2003/0022,836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | 5 | 2002 | |
7915395 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell | 4 | 2002 | |
* 2004/0022,787 Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID | 40 | 2003 | |
7311910 Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions | 6 | 2003 | |
* 2005/0169,919 CTLA4 molecules and IL4-binding molecules and uses thereof | 4 | 2003 | |
7541164 Mammalian cell culture processes for protein production | 20 | 2003 | |
7332303 Product quality enhancement in mammalian cell culture processes for protein production | 66 | 2003 | |
* 2005/0084,933 Product quality enhancement in mammalian cell culture processes for protein production | 7 | 2003 | |
* 2005/0019,859 Mammalian ceII culture processes for protein production | 12 | 2003 | |
7307064 Methods for treating cardiovascular disease using a soluble CTLA4 molecule | 19 | 2004 | |
* 2005/0123,539 Methods for treating cardiovascular disease using a soluble CTLA4 molecule | 4 | 2004 | |
7439230 Methods of treatment using CTLA4 mutant molecules | 8 | 2004 | |
7572772 Soluble CTLA4 mutant molecules | 4 | 2007 | |
7700556 Methods of treatment using CTLA4 mutant molecules | 6 | 2007 | |
7671022 Methods for treating cardiovascular disease using a soluble CTLA4 molecule | 1 | 2007 | |
7829534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | 3 | 2007 | |
7915222 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis | 4 | 2009 | |
8227420 Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID | 3 | 2010 | |
8148332 Method for treating a rheumatic disease using a soluble TLA4 molecule | 3 | 2011 | |
8785398 Methods of treatment using CTLA4 mutant molecules | 0 | 2011 | |
8497247 Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule | 3 | 2012 | |
8722632 Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule | 0 | 2013 | |
8703718 Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule | 0 | 2013 | |
9012408 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis | 0 | 2013 | |
9296808 Methods for treating scleroderma by administering a soluble CTLA4 molecule | 0 | 2014 | |
9758565 Methods of treatment using CTLA4 mutant molecules | 0 | 2014 | |
|
|||
* 7183376 Variant B7 co-stimulatory molecules | 0 | 2001 | |
* 2003/0138,881 Novel co-stimulatory molecules | 6 | 2001 | |
* 2005/0154,189 Novel co-stimulatory molecules | 2 | 2004 | |
7612170 Co-stimulatory polypeptides | 0 | 2006 | |
|
|||
7794710 Methods of enhancing T cell responsiveness | 33 | 2002 | |
* 2003/0039,653 Methods of enhancing T cell responsiveness | 31 | 2002 | |
* 7432351 B7-H1 variants | 16 | 2003 | |
9062112 B7-H1, a novel immunoregulatory molecule | 1 | 2008 | |
* 2009/0274,666 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE | 10 | 2008 | |
8981063 B7-H1 Antibodies | 3 | 2009 | |
* 2009/0317,368 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE | 11 | 2009 | |
8747833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer | 3 | 2011 | |
8460927 B7-H1 antibodies and method of use | 5 | 2011 | |
9803015 Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target | 0 | 2016 | |
|
|||
7754209 Binding constructs and methods for use thereof | 23 | 2003 | |
|
|||
* 6071716 DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells | 15 | 1993 | |
6653444 Polypeptides comprising a B7 extracellular domain | 6 | 1995 | |
* 2002/0182,727 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells | 4 | 2002 | |
* 2006/0233,795 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells | 0 | 2006 | |
|
|||
* 2005/0238,646 Binding domain-immunoglobulin fusion proteins | 89 | 2005 | |
* 2005/0202,012 Binding domain-immunogloubulin fusion proteins | 31 | 2005 | |
* 2005/0202,023 Binding domain-immunoglobulin fusion proteins | 76 | 2005 | |
* 2005/0202,534 Binding domain-immunoglobulin fusion proteins | 79 | 2005 | |
* 2005/0186,216 Binding domain-immunoglobulin fusion proteins | 35 | 2005 | |
* 2005/0180,970 Binding domain-immunoglobulin fusion proteins | 33 | 2005 | |
* 2005/0175,614 Binding domain-immunoglobulin fusion proteins | 76 | 2005 | |
|
|||
7029674 Methods for downmodulating immune cells using an antibody to PD-1 | 77 | 2002 | |
8088905 Nucleic acids encoding antibodies against PD-1 | 8 | 2009 | |
* 2010/0028,330 METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES | 6 | 2009 | |
|
|||
* 7244822 BTL-II proteins | 0 | 2003 | |
* 2004/0209,289 BTL-II nucleic acids, proteins, and antibodies | 0 | 2003 | |
7709618 BTL-II nucleic acids | 0 | 2007 | |
* 2009/0142,801 BTL-II NUCLEIC ACIDS | 0 | 2007 | |
8173603 Methods of using BTL-II proteins | 0 | 2010 | |
* 2010/0330,104 METHODS OF USING BTL-II PROTEINS | 0 | 2010 | |
8674078 Methods of using BTL-II proteins | 1 | 2012 | |
|
|||
* 2003/0161,827 Therapies that improve graft survival | 5 | 2002 | |
|
|||
* 2003/0133,939 Binding domain-immunoglobulin fusion proteins | 171 | 2002 | |
7754208 Binding domain-immunoglobulin fusion proteins | 29 | 2002 | |
|
|||
* 2004/0058,445 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB | 31 | 2002 | |
|
|||
9050352 Immunomodulating compositions and uses therefor | 2 | 2004 | |
* 2007/0207,161 Immunomodulating Compositions and uses Therefor | 38 | 2004 | |
9770503 Immunomodulating compositions and uses therefor | 0 | 2015 | |
|
|||
* 6638741 Differentiation-suppressive polypeptide serrate-2 | 0 | 2001 | |
|
|||
* 2002/0150,993 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same | 9 | 2002 | |
7807153 Apo-2 receptor agonist antibodies | 0 | 2003 | |
* 2004/0009,552 Apo-2 receptor | 12 | 2003 | |
* 2005/0069,983 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same | 6 | 2004 | |
7750118 Apo-2 receptor polypeptides | 0 | 2005 | |
* 2006/0035,334 Apo-2 receptor | 11 | 2005 | |
7749755 Apo-2 receptor polynucleotides | 0 | 2005 | |
7595046 Treatment of cancer using anti-Apo-2 antibodies | 2 | 2005 | |
* 2006/0141,573 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same | 6 | 2005 | |
7939631 APO-2 receptor polypeptides | 0 | 2010 | |
8092799 Antibodies to Apo-2 receptor polypeptides | 0 | 2010 | |
* 2011/0008,354 ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES | 1 | 2010 | |
|
|||
7829084 Binding constructs and methods for use thereof | 18 | 2003 | |
* 2005/0136,049 Binding constructs and methods for use thereof | 74 | 2003 | |
8106161 Binding domain-immunoglobulin fusion proteins | 6 | 2005 | |
8333966 CD37 immunotherapeutics and uses thereof | 6 | 2009 | |
* 2011/0171,208 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF | 11 | 2009 | |
9101609 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof | 0 | 2009 | |
8147835 Binding domain-immunoglobulin fusion proteins | 5 | 2009 | |
8197810 Binding domain-immunoglobulin fusion proteins | 3 | 2010 | |
8188237 Binding domain-immunoglobulin fusion proteins | 3 | 2010 | |
8853366 Binding domain-immunoglobulin fusion proteins | 0 | 2012 | |
9005612 Binding domain-immunoglobulin fusion proteins | 6 | 2012 | |
|
|||
7175847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 | 6 | 2000 | |
7192585 CD80 specific antibodies | 8 | 2005 | |
* 2005/0260,205 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof | 0 | 2005 | |
7425447 Host cells expressing 7C10 and 16C10 CD80-specific antibodies | 2 | 2006 | |
7414123 Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies | 0 | 2006 | |
* 2008/0038,254 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens | 0 | 2006 | |
* 2006/0275,291 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens | 0 | 2006 | |
7417128 7C10 and 16C10 CD80-specific antibodies | 2 | 2006 | |
* 2007/0128,185 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2006 | |
7510712 Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies | 2 | 2007 | |
7510713 Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies | 0 | 2007 | |
7501264 Methods of producing 7C10 and 16C10 CD80-specific antibodies | 0 | 2007 | |
7491393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies | 2 | 2007 | |
* 2009/0012,271 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2007 | |
* 2009/0010,939 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2007 | |
* 2008/0114,156 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2007 | |
* 2008/0095,769 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2007 | |
|
|||
* 7446189 Nucleic acids encoding mutant human CD80 and compositions comprising the same | 2 | 2000 | |
|
|||
* 6685941 Methods of treating autoimmune disease via CTLA-4Ig | 28 | 1995 | |
|
|||
7435796 Antibodies which bind B7RP1 | 7 | 2000 | |
* 8624010 Nucleic acids encoding B7RP1 | 0 | 2000 | |
* 7153669 Nucleic acids encoding MK61 receptors | 1 | 2001 | |
* 2002/0150,977 TNF receptor-like molecules and uses thereof | 0 | 2001 | |
* 7569387 Antibody to TNF receptor-like molecules | 0 | 2006 | |
* 2008/0152,651 Novel polypeptides involved in immune response | 3 | 2007 | |
8470317 B7RP-1 antagonists | 0 | 2008 | |
8309083 Polypeptides involved in immune response | 0 | 2010 | |
* 2011/0059,068 POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE | 3 | 2010 | |
|
|||
6926895 Treatment of Crohn's disease using anti-CD80 antibodies that do not inhibit the binding of CD80 antigen to CTLA-4 | 0 | 2000 | |
* 2009/0124,791 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS | 0 | 2008 | |
|
|||
7053181 Canine and feline B7-2 proteins, compositions and uses thereof | 0 | 2004 | |
7385045 Canine B7-1 nucleic acid molecules | 2 | 2005 | |
|
|||
* 6261801 Nucleic acids encoding tumor necrosis factor receptor 5 | 4 | 1998 | |
7511017 Methods of treatment with TNFR5 | 0 | 2005 | |
|
|||
7011833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent | 5 | 2000 | |
7521532 GL50 polypeptides | 7 | 2002 | |
* 7459544 Nucleic acids encoding B7-2 fusion proteins | 1 | 2003 | |
* 7601813 Anti-GL50 antibodies | 7 | 2005 | |
* 2006/0099,635 Anti-GL50 antibodies | 6 | 2005 | |
7976840 Use of anti-GL50 antibodies for the downmodulation of an immune response | 1 | 2009 |
Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events

Matter Detail

Renewals Detail

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Advertisement

Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
PAIR load has been initiated
A preliminary load of cached data will be loaded soon. Current PAIR data will be loaded within twenty four hours.
File History PDF
Thank you for your purchase! The File Wrapper for Patent Number 5580756 will be available within the next 24 hours.
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:

Last Refreshed On:
Changes done successfully
Important Notes on Latency of Status data
Please note there is up to 60 days of latency in this Status indicator for certain status conditions. You can obtain up-to-date Status indicator readings by ordering PAIR for the file.
An application with the status "Published" (which means it is pending) may be recently abandoned, but not yet updated to reflect its abandoned status. However, an application filed less than one year ago is unlikely to be abandoned.
A patent with the status "Granted" may be recently expired, but not yet updated to reflect its expired status. However, it is highly unlikely a patent less than 3.5 years old would be expired.
An application with the status "Abandoned" is almost always current, but there is a small chance it was recently revived and the status not yet updated.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.